News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Pioneer in building collaboration across research fields joins as Scientific Director of the Cancer Research UK Convergence Science Centre
The Institute of Cancer Research, London, and Imperial College London have appointed a leading expert in building interdisciplinary partnerships to head our joint Cancer Research UK Convergence Science Centre.
ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer
Genetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease, a new pilot study shows.
ASCO 2020: Blood test predicts response to prostate cancer treatment
A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease.
ASCO 2020: New optimised precision radiotherapy can reduce swallowing difficulties for head and neck cancer patients
A new optimised intensity-modulated radiation therapy (IMRT) could spare head and neck cancer patients’ adverse life-long side effects after treatment, new clinical trial results have shown.
-547x410.jpg?sfvrsn=c727183b_2 "Non-small cell lung cancer (photo Dr Ed Uthman-Yale Rosen-Flickr) 547x410")
AI could predict risk of lung cancer coming back
Computer scientists working with pathologists have trained an artificial intelligence (AI) tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment.
Prostate cancer gets first gene-targeted medicines
The Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer.
Thousands of lives could be lost to delays in cancer surgery during COVID-19 pandemic
Delays to cancer surgery and other treatment caused by the coronavirus crisis could result in thousands of additional deaths linked to the pandemic in England, a major new study reports.
Mapping how evolutionary forces affect cancer growth could help doctors choose biopsies
A computer model that uses the principles of evolution to map the growth of populations of cancer cells in tumours could help doctors choose where to take biopsies from tumours, improving decisions about treatment.
New life-sciences incubator space plans announced for The London Cancer Hub
Life-science companies will have the opportunity to work directly alongside world-class scientists from The Institute of Cancer Research, London, after exciting plans were revealed to create a new innovation centre.
Scientists bring together world’s coronavirus research in 'intelligent' online database
Scientists have created a dynamic database driven by artificial intelligence which is collecting together the world’s research on coronavirus in a single online space.
Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’
The Institute of Cancer Research, London, has broadly welcomed the approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer.
One-week course of radiotherapy could benefit women with early stage breast cancer, study finds
A one-week course of radiotherapy in fewer but larger daily doses was found to be as safe and effective as standard three-week therapy for women following surgery for early stage breast cancer. The protocol is being eagerly sought by hospitals to help reduce demands on the NHS during the COVID-19 pandemic.
